IL1B and type 2 diabetes mellitus: Anti-inflammatory agents such as salicylates, TNF-α antagonists, IL-1β antagonists, leukotrienes, and CA may be useful in developing therapeutics for obesity-related diseases, including insulin resistance, type 2 diabetes, and atherosclerotic cardiovascular disease [71].